Analysis of endometrial cancer staging systems
Clinicopathological Analysis of Endometrial Carcinoma in the View of Old and New International Federation of Gynecology and Obestetrics (FIGO)
This study is testing how a new way of staging endometrial cancer affects treatment decisions and outcomes for patients with the disease.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 110 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | Assiut University Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Asyut) |
| Trial ID | NCT06632431 on ClinicalTrials.gov |
What this trial studies
This study evaluates the transition from the FIGO 2009 to the FIGO 2023 endometrial cancer staging system, focusing on how this change affects stage classification, risk stratification, and patient survival outcomes. It aims to assess the prognostic impact of the new staging system and its influence on adjuvant management decisions for patients diagnosed with endometrial carcinoma. By analyzing data from patients who underwent surgical staging, the study seeks to provide insights that could enhance treatment strategies and patient care.
Who should consider this trial
Good fit: Ideal candidates include women diagnosed with endometrial cancer who underwent surgical staging and have available medical records and follow-up data.
Not a fit: Patients who received neoadjuvant chemotherapy, have recurrent endometrial cancer, or lack necessary medical records and histopathological materials may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved prognostic predictions and treatment decisions for patients with endometrial cancer.
How similar studies have performed: Other studies have shown success with similar approaches in refining cancer staging systems, indicating potential for meaningful advancements.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: \- Patients diagnosed with endometrial cancer (EC) who underwent surgical staging (total hysterectomy and bilateral salpingo-oophorectomy) between January 1, 2018, and December 31, 2022 with available medical records since diagnosis and at least follow up 2 years and received adjuvant treatment and available histopathological slides and blocks. Exclusion Criteria: \- Patients who received neoadjuvant chemotherapy, had recurrent endometrial cancer, had multiple cancers, lacked histopathological slides and formalin-fixed paraffin-embedded blocks or lacked medical records were excluded
Where this trial is running
Asyut
- Assiut university — Asyut, Egypt (Recruiting)
Study contacts
- Study coordinator: Yousra H Abdelghafour, MBBCH
- Email: yousrahamzawy1997@gmail.com
- Phone: 00201149264064
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.